Yi Tai, Rao Deepak A, Tang Paul C Y, Wang Yinong, Cuchara Lisa A, Bothwell Alfred L M, Colangelo Christopher M, Tellides George, Pober Jordan S, Lorber Marc I
Interdepartmental Program in Vascular Biology and Transplantation, Yale University School of Medicine, New Haven, CT, USA.
Transplantation. 2008 Sep 15;86(5):719-27. doi: 10.1097/TP.0b013e318183eefa.
Graft arteriosclerosis (GA) is an important factor limiting long-term outcomes after organ transplantation. We have used a chimeric humanized mouse system to model this arteriopathy in human vessels, and found that the morphologic and functional changes of experimental GA are interferon (IFN)-gamma dependent. This study evaluated whether 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, described as inhibitors of IFN-gamma production, affect GA in our model.
C.B.-17 severe combined immunodeficiency-beige mice were transplanted with human artery segments as aortic interposition grafts and inoculated with allogeneic human peripheral blood mononuclear cells (PBMCs) or replication-deficient adenovirus encoding human IFN-gamma. Transplant arteries were analyzed from recipients treated with vehicle vs. atorvastatin or simvastatin at different doses. The effects of statins on T-cell alloresponses to vascular endothelial cells were also investigated in vitro.
Graft arteriosclerosis-like arteriopathy induced by PBMCs was reduced by atorvastatin at 30 mg/kg/day or simvastatin at 100 mg/kg/day that correlated with decreased graft-infiltrating CD3+ T cells. Circulating IFN-gamma was also reduced, as were graft IFN-gamma and IFN-gamma-inducible chemokine transcripts and graft human leukocyte antigen-DR expression. Graft arteriosclerosis directly induced by human IFN-gamma in the absence of human PBMCs was also reduced by atorvastatin, but only at the highest dose of 100 mg/kg/day. Finally, atorvastatin decreased the clonal expansion and production of interleukin-2, but not IFN-gamma, by human CD4+ T cells in response to allogeneic endothelial cells in coculture.
Our results suggest that a benefit of statin administration in transplantation may include amelioration of GA primarily by inhibiting alloreactive T-cell accumulation and consequent IFN-gamma production and secondarily through suppression of the arterial response to IFN-gamma.
移植血管动脉硬化(GA)是限制器官移植长期预后的重要因素。我们利用嵌合人源化小鼠系统在人体血管中模拟这种动脉病变,发现实验性GA的形态学和功能变化依赖于干扰素(IFN)-γ。本研究评估了被描述为IFN-γ产生抑制剂的3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂是否会影响我们模型中的GA。
将人动脉段作为主动脉间置移植物移植到C.B.-17严重联合免疫缺陷-米色小鼠体内,并接种异体人外周血单个核细胞(PBMC)或编码人IFN-γ的复制缺陷型腺病毒。对接受不同剂量载体、阿托伐他汀或辛伐他汀治疗的受体的移植动脉进行分析。还在体外研究了他汀类药物对T细胞对血管内皮细胞同种异体反应的影响。
PBMC诱导的移植血管动脉硬化样动脉病变在阿托伐他汀剂量为30mg/kg/天或辛伐他汀剂量为100mg/kg/天时减轻,这与移植组织中浸润的CD3+T细胞减少相关。循环IFN-γ也减少,移植组织中的IFN-γ、IFN-γ诱导的趋化因子转录本以及移植组织中人白细胞抗原-DR表达也减少。在无人PBMC情况下由人IFN-γ直接诱导的移植血管动脉硬化也被阿托伐他汀减轻,但仅在最高剂量100mg/kg/天时有效。最后,阿托伐他汀减少了人CD4+T细胞在共培养中对异体内皮细胞反应时白细胞介素-2的克隆扩增和产生,但不影响IFN-γ的产生。
我们的结果表明,他汀类药物在移植中的益处可能包括主要通过抑制同种异体反应性T细胞积累及随后的IFN-γ产生,以及其次通过抑制动脉对IFN-γ的反应来改善GA。